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Abstract
Inflammatory mediators in the tumour microenvironment promote tumour growth, vascular development and enable
evasion of anti-tumour immune responses, by disabling infiltrating dendritic cells. However, the constituents of the tumour
microenvironment that directly influence dendritic cell maturation and function are not well characterised. Our aim was to
identify tumour-associated inflammatory mediators which influence the function of dendritic cells. Tumour conditioned
media obtained from cultured colorectal tumour explant tissue contained high levels of the chemokines CCL2, CXCL1,
CXCL5 in addition to VEGF. Pre-treatment of monocyte derived dendritic cells with this tumour conditioned media inhibited
the up-regulation of CD86, CD83, CD54 and HLA-DR in response to LPS, enhancing IL-10 while reducing IL-12p70 secretion.
We examined if specific individual components of the tumour conditioned media (CCL2, CXCL1, CXCL5) could modulate
dendritic cell maturation or cytokine secretion in response to LPS. VEGF was also assessed as it has a suppressive effect on
dendritic cell maturation. Pre-treatment of immature dendritic cells with VEGF inhibited LPS induced upregulation of CD80
and CD54, while CXCL1 inhibited HLA-DR. Interestingly, treatment of dendritic cells with CCL2, CXCL1, CXCL5 or VEGF
significantly suppressed their ability to secrete IL-12p70 in response to LPS. In addition, dendritic cells treated with a
combination of CXCL1 and VEGF secreted less IL-12p70 in response to LPS compared to pre-treatment with either cytokine
alone. In conclusion, tumour conditioned media strongly influences dendritic cell maturation and function.
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Introduction
Dendritic cells (DCs) are potent antigen presenting cells capable
of activating naı ¨ve T cells. DCs are present in tissues in an
immature state and display low levels of maturation or co-
stimulatory markers such as CD83, CD80 or CD86. Immature
DCs (iDCs) recognise and capture specific antigens, including
tumour antigens. DCs undergo a functional maturation process in
response to inflammatory mediators such as IFN-a or Toll like
receptor (TLR) agonists. As DCs mature they gain the potential of
presenting antigen to T cells and activating a specific anti-tumour
T cell response [1,2]. DCs that secrete high levels of bioactive IL-
12p70 induce optimal anti-tumour immunity, as they have
increased capacity to enhance natural killer cell activity, skew
the response to Th1 and prime tumour specific CD8
+ T cells [3,4].
However, many tumours evade the immune response by
secreting cytokines and other factors that inhibit DC differentia-
tion or the maturation of tumour infiltrating DCs. [1]. One of
these ‘pro-tumour’ factors, Vascular Endothelial Growth Factor
(VEGF) is known for sustaining tumour growth via its angiogenic
properties but can also elicit an inhibitory effect on DC
differentiation and maturation, enhancing tumour survival
[1,5,6,7,8]. VEGF has successfully been targeted by the human-
ised monoclonal antibody Bevacizumab (Avastin) [9], however
response rates are approximately 40% and many patients develop
resistance to this treatment. Therefore, it is crucial to explore the
potential of other inflammatory mediators present in the tumour
microenvironment that may inhibit DC maturation, as these may
also be potential therapeutic targets.
Several cytokines and chemokines are present at high levels in
the tumour microenvironment, compared to normal tissues, such
as CCL2 (MCP-1), CXCL1 (GROa) and CXCL5 (ENA-78)
[10,11,12]. CCL2 is known to attract monocytes, T-cells and
dendritic cells [10,13], while the main function of CXCL1 and
CXCL5 is to attract and activate neutrophils [14,15]. In addition
to their chemoattractant functions, CCL2, CXCL1 and CXCL5
also play an important role in angiogenesis [15,16,17], demon-
strating the multifunctional nature of these chemokines. It is
known that human myeloid DCs express CCR2 and CXCR2, the
receptors for CCL2 and CXCL1 and CXCL5, respectively
[18,19]. However the effect of these chemokines on DC
maturation and function has not previously been investigated.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27944In this study, we used explanted human colorectal cancer
tissue to model the tumour microenvironment [20]. Explant
tissues maintain the complex 3D structure of the tumour,
including the stroma, thus allowing the production of many
different tumour associated factors, closely mimicking the
inflammatory milieu of the tumour in situ. Previous studies have
shown that supernatants from tumour cell lines can inhibit DC
maturation [21,22], however the importance of factors secreted
by the entire tumour on dendritic cell maturation has not been
previously examined.
We demonstrate that Tumour Conditioned Media (TCM)
from cultured colorectal cancer tumours significantly inhibited
LPS induced DC maturation, markedly increasing IL-10 while
decreasing IL-12p70 secretion in response to LPS. We found
that the TCM contained significant amounts of the chemokines
CCL2, CXCL1 and CXCL5 in addition to VEGF. Levels of
CCL2, CXCL1 and CXCL5 in the TCM correlated with CD83
expression and IL-12p70 secretion from DCs treated with TCM.
Individually, all of these inflammatory mediators significantly
inhibited LPS induced IL-12p70 secretion, however IL-10
secretion remained unaffected. Interestingly, the effects of
CXCL1 and VEGF on the inhibition of LPS induced IL-
12p70 secretion by DCs were additive. In addition, CXCL1 also
had a marked inhibitory effect on LPS induced up-regulation of
HLA-DR.
Results
Tumour conditioned media inhibits DC maturation and
IL-12p70 secretion while augmenting IL-10 secretion in
response to LPS
Monocyte derived DCs obtained from 2 healthy volunteers
were incubated with different volumes of TCM from 4 colorectal
cancer patients for 4 hours prior to LPS simulation for a further
18 hours, to determine the optimal concentration of TCM. We
examined the effect of TCM on the ability of DCs to secrete IL-10
and IL-12p70 in response to stimulation by LPS. Secretion of IL-
12p70 by DCs augments and directs the expansion and
differentiation of tumour specific Th1 responses while high levels
of IL-10 secretion preferentially leads to the expansion of
immunosuppressive T regulatory cells. Treatment of DCs with a
1 in 2 dilution of TCM showed to have the most potent effect on
IL-10 increase and IL-12p70 inhibition (p=0.028) in response to
LPS (Figure 1). No significant difference was observed in
expression of CD80, CD86, CD54, CD83 and HLA-DR (MHC
II), markers associated with DC maturation, between different
dilutions of TCM (data not shown). Therefore we used a 1 in 2
dilution of TCM for further analysis.
Monocyte derived DCs obtained from 6 healthy donors were
treated with 1 in 2 TCM of 21 colorectal patients for 4 hours
before treatment with LPS for a further 18 hours, and interest-
ingly, TCM treated DCs secreted significantly higher levels of IL-
10 in response to LPS (p,0.0001), but significantly lower levels of
IL-12p70 (p,0.0001) (Figure 2A). In addition IL-12p70 showed a
negative correlation with CD83 expression Spearman r=20.71,
p,0.001 (data not shown), further suggesting that TCM treated
DCs with increasing CD83 expression have decreasing levels of
IL-12p70 secretion.
Treatment of DCs with TCM also significantly inhibited LPS-
induced DC maturation, with reduced expression of CD54
(p,0.0001), CD86 (p=0.0035), HLA-DR (p=0.0474) and CD83
(p=0.0018) observed (Figure 2B & C). Treatment of DCs with
conditioned media taken from normal tissue adjacent to the
tumour tissue (NCM) did not inhibit LPS induced maturation or
cytokine secretion from DCs (Figure 3).
Levels of CCL2, CXCL1, and CXCL5 present in TCM
correlate with CD83 expression and IL-12p70 secretion
from DCs
TCM obtained from 21 patients with colorectal cancer were
analysed by ELISA for several known tumour associated factors.
Levels of CCL2, CXCL1 and CXCL5 were consistently higher
than those of VEGF (a current therapeutic target in colorectal
Figure 1. Tumour Conditioned Media affects IL-10 and IL-
12p70 secretion in a dose dependent manner. Immature
monocyte derived dendritic cells (iDCs) (n=2) were treated for 4 hours
with 1:2, 1:4 and 1:10 dilutions of Tumour Conditioned Media (TCM)
obtained by culturing the explanted tumours of 4 colorectal cancer
patients in vitro for 72 hours. LPS (1 mg/mL) was added and the cells
were cultured for a further 18 hours. Supernatants were collected from
the cells cultured as described above, and the levels of IL-10 and IL-
12p70 secretion by the DCs were measured by ELISA. Statistical
differences were determined by Mann-Whitney U test.
doi:10.1371/journal.pone.0027944.g001
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(Spearman r=0.59, p=0.0053) CXCL1 (Spearman r=0.50,
p=0.0202) and CXCL5 (Spearman r=0.50, p=0.0199) present
in the TCM positively correlated with CD83 expression on DCs
treated with TCM (Figure 4A). This implies that with increasing
levels of CCL2, CXCL1 and CXCL5 present in the TCM, CD83
expression is elevated on DCs treated with TCM. Even though
VEGF is present at detectable levels in the TCM, it showed
no correlation with DC maturation. In addition we found that
IL-12p70 secretion from DCs treated with TCM negatively
correlated with CCL2 (Spearman r=20.64, p=0.0019), CXCL1
(Spearman r=20.59, p=0.0049) and CXCL5 (Spearman
r=20.57, p=0.0075) (Figure 4B). This suggests that with
increasing levels of CCL2, CCL1 and CXCL5 in the TCM,
IL-12p70 secretion from DCs decreases. There was no significant
correlation between the four cytokines and the other DC
markers, CD80, CD54, CD86, and HLA-DR, and IL-10
secretion.
Figure 2. Tumour Conditioned Media inhibits dendritic cell maturation, augments IL-10 while inhibiting IL-12p70 secretion
induced by LPS. iDC (n=6) were treated with TCM of 21 colorectal cancer patients for 4 hours before adding LPS; the cells were cultured for a
further 18 hours. Levels of IL-10 and IL-12p70 secretion by the DCs were measured by ELISA. Statistical differences were determined by ANOVA. (A)
Expression of the following maturation markers: CD80, CD54, CD86, HLA-DR, and CD83 were assessed by flow cytometry. One representative
experiment of six is shown (B). The Fold Change in M.F.I. of each marker was calculated relative to unstimulated iDCs for cells treated with LPS or
TCM+LPS. Statistical significance was calculated using the Wilcoxon signed rank test. (C). * p,0.05, ** p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0027944.g002
Tumour Microenvironment Inhibits Dendritic Cells
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27944Effect of CCL2, CXCL1, CXCL5 and VEGF on DC
maturation marker expression and cytokine secretion in
response to LPS
Having established that TCM inhibits DC maturation in
response to LPS and that TCM contains high levels of the
chemokines CCL2, CXCL1 and CXCL5 we next determined if
these individual components had a direct effect on DCs.
Recombinant VEGF significantly inhibited LPS-induced expres-
sion of DC maturation markers CD80 (p=0.0391) and CD54
(p=0.0078) and CXCL1 significantly inhibited the upregulation of
HLA-DR (p=0.0156) (Data not shown). Although CCL2 and
CXCL5 showed a reduction of LPS-induced maturation of DCs,
this did not reach statistical significance (Data not shown). While
the pre-treatment of DCs with CCL2, CXCL1, CXCL5 or VEGF
failed to augment LPS-induced IL-10 secretion, a significant
decrease in the levels of LPS-induced IL-12p70 secretion was
observed: CCL2 (p=0.048), CXCL1 (p=0.0068), CXCL5
(p=0.0255), VEGF (p=0.0402) (Figure 5). IL-1b, TNF-a, IL-8
and IL-6 production by DCs in response to LPS in the absence or
presence of pre-treatment with VEGF, CCL2, CXCL1 or CXCL5
were also measured; however there were no significant differences
in the levels of these cytokines determined under these conditions
(data not shown). Treatment of DCs with CCL2, CXCL1,
CXCL5 and VEGF did not affect their ability to induce T cell
proliferation or production of IFNc (data not shown).
In addition we investigated whether CCL2, CXCL1, CXCL5
and VEGF could affect DC migration. CCL19 was used as a
positive control since it is known to bind to the chemokines
receptor CCR7, which is expressed by DCs [23]. We found that
they did not increase migration compared to CCL19 (data not
shown).
CXCL1 and VEGF have an additive inhibitory effect on IL-
12p70 secretion by DCs in response to LPS
The TCM has a potent inhibitory effect on DC maturation and
function, but CCL2 and CXCL5, which are present at high levels
in TCM, do not have a significant effect on dendritic cell
maturation marker expression, while CXCL1 only significantly
inhibited HLA-DR and VEGF significantly inhibited CD80 and
CD54 (data not shown). Therefore, we investigated whether
combining the recombinant cytokines might have a more potent
effect on dendritic cell maturation. We examined seven different
combinations of the four cytokines: CCL2+CXCL1, CCL2+CXCL5,
CCL2+VEGF, CXCL1+CXCL5, CXCL1+VEGF, CXCL5+
VEGF, CCL2+CXCL1+CXCL5+VEGF. The combination of
CXCL1 and VEGF did not significantly inhibit LPS-induced
maturation marker expression by DCs (CD80 p=0.0625, CD54
p=0.6,CD86p=0.6,HLA-DRp=0.1,CD83p=0.8)(Figure6A).
However combining CXCL1 and VEGF significantly reduced LPS-
induced IL-12p70 (p=0.0028), but did not alter the levels of IL-10
(Figure 6B). IL-1b,T N F a, IL-8 or IL-6 secretions were not altered
(data not shown). No other combination had a direct effect on LPS-
induced DC maturation or cytokine secretion of DCs in response to
LPS when compared to the individual cytokines (data not shown). In
addition inclusion of neutralising antibodies to CXCL1 and VEGF,
alone and in combination, did not correct TCM induced alteration of
DC maturation, IL-10 or IL-12p70 secretion from DCs in response to
LPS (data not shown).
Discussion
In this study we have shown for the first time that tumour
conditioned media from colorectal cancer tumour explants can
significantly inhibit LPS-induced maturation of monocyte derived
DCs. In addition, treatment of DCs with TCM prior to LPS
stimulation significantly increased production of IL-10, an anti-
inflammatory cytokine that inhibits a Th1 response [24], while
decreasing the secretion of IL-12p70, a pro-inflammatory cytokine
required for Th1 responses: a DC phenotype associated with
tolerance. Subsequently, we found that CCL2, CXCL1 and
CXCL5 were expressed at high levels in the TCM compared to
VEGF, and we determined if these inflammatory mediators could
alter the function of DCs. VEGF was included in our analyses as it
had previously been shown to inhibit DC maturation [8,22]. The
addition of recombinant VEGF to iDCs had an inhibitory effect
on the LPS-induced upregulation of CD80 and CD54, while
adding recombinant CXCL1 to iDCs decreased HLA-DR
expression following LPS treatment.
However, treatment of iDCs with human recombinant CCL2,
CXCL1, CXCL5 or VEGF, at doses in line with other studies
[13,22,25,26], resulted in significantly reduced levels of IL-12p70
secretion in response to LPS stimulation. These data suggest that
inflammatory mediators present in the tumour microenvironment
reduce the capacity of local DCs to secrete IL-12p70 and thus the
induction of an effective anti-tumour response.
Similar findings were reported in a study investigating the effect
of conditioned media taken from the pancreatic cancer cell line
BxPC-3 (BxCM), where DC differentiation and maturation was
inhibited by BxCM. The study showed that BxCM reduced the
expression of CD83, CD1a, CD1c, CD80 and CD86 by DCs in
response to TNFa. Consistent with our findings, this study found a
significant increase in IL-10 and a reduction in IL-12p70
production in response to stimulation with TNFa following
BxCM treatment [27]. However, the treatment of DCs with
supernatant of RCC-10 (renal cell carcinoma cells), resulted in a
reduction in the expression of maturation markers, but did not
affect IL-10 production in response to stimulation with TNFa,
IFNa and poly I:C [22]. These studies, together with the data
presented here, suggest that many tumour types secrete inflam-
matory mediators that can inhibit the functionality of DCs; but
that there is likely to be variation in the inflammatory milieu and
Figure 3. Normal Conditioned media does not affect LPS
induced DC maturation. Normal conditioned media (NCM) of 5
colorectal cancer patients was used to treat monocyte derived DCs
before adding LPS. Expression of CD80, CD54, CD86, HLA-DR and CD83
was measured by flow cytometry. No statistical significant difference
was observed. Statistical analysis was performed using the Wilcoxon
signed rank test.
doi:10.1371/journal.pone.0027944.g003
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stage. While it would have been interesting to assess and isolate the
actual levels of DC infiltration in the tumour explant tissue, this
could not be performed due to the limitation of explant tissue size
we received from surgery. Our results indicate that NCM does not
significantly affect DC maturation or cytokine secretion, indicating
that the normal adjacent tissue may have functional immunity.
There was no evidence of an immunosuppressive field effect.
VEGF is established as an important factor contributing to
tumour growth by inducing angiogenesis. VEGF is a therapeutic
target in several cancers, including colorectal cancer, where the
humanised anti-VEGF mAb, Bevacizumab (Avastin) is employed.
Previous studies have demonstrated that VEGF inhibits DC
maturation and DCs ability to activate T cells [5,8,22]. In this
study, we demonstrate that VEGF inhibits the expression of CD80
and CD54, but not CD86 or HLA-DR, data consistent with Alfaro
et al. [22]. Interestingly, we found that VEGF treated DCs secreted
significantly reduced levels of IL-12p70 in response to LPS; a
finding that has not been previously documented. The use of LPS
to mature the DCs, versus the maturation cocktail consisting of
TNFa, IFNa and poly I:C used by Alfaro et al. might explain the
differences observed in the effect of VEGF on DC maturation and
IL-12p70 secretion. Our finding that VEGF stimulation of DCs
does not affect T cell proliferation and cytokine secretion is
consistent with Alfaro et al., however they found an inhibitory
effect of VEGF when present at the differentiation stage of DC
development, indicating that differentiated DCs might be less
responsive to the effects of VEGF [22]. Our study also showed that
our colorectal cancer patients explant tissue secreted high levels of
CCL2, CXCL1 and CXCL5, compared to VEGF. Interestingly,
CCL2, CXCL1 and CXCL5 levels in TCM correlated with CD83
expression on TCM treated DCs. This is the first time this
correlation has been observed, and suggests that patients with
higher levels of CCL2, CXCL1 or CXCL5 might have increased
Figure 4. Levels of CCL2, CXCL1, and CXCL5 in TCM correlate with CD83 expression and IL-12p70 secretion. Concentrations of CCL2,
CXCL1, CXCL5 and VEGF in tumour conditioned media of 21 colorectal cancer patients were measured by ELISA. The concentrations of CCL2, CXCL1
and CXCL5 correlated with expression of CD83 on DCs treated with TCM (A). CCL2, CXCL1 and CXCL5 inversely correlated with secretion of IL-12p70
from dendritic cells treated with the TCM (B). The Spearman rank correlation test was used.
doi:10.1371/journal.pone.0027944.g004
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and B cell activation [28,29], however we also found that
enhanced expression of CD83 on DCs treated with TCM
correlated with reduced IL-12p70 secretion from TCM treated
DCs. It has been previously reported that while different stimuli
might mature DCs to similar levels, with similar expression of
CD83, CD80 and CD86, the profile of cytokines that they secrete
differ; stimuli such as IFN-c can result in IL-12 secreting CD83+
DCs that stimulate Th1 responses while other stimuli such as
prostaglandin E2 result in CD83+ DCs that secrete no IL-12 but
efficiently promote a Th2 response [30].
While it has been reported that CCL2, CXCL1 and CXCL5
are important for tumour growth, proliferation, and angiogenesis
[31,32], the effect of these chemokines on DCs has not previously
been documented. CCL2, CXCL1 and CXCL5 levels in TCM
correlated inversely with IL-12p70 secretion, this is the first time
this correlation has been observed, and suggests that with
increasing levels of CCL2, CXCL1 and CXCL5 in the TCM,
IL-12p70 secretion from DCs is reduced. CCL2 is a chemoat-
tractant for monocytes, memory T-cells and dendritic cells
[26,31]. CCL2 has also been previously reported to induce
angiogenesis [17], which is important for tumour growth and
metastasis. Both pro- and anti-tumour effects of CCL2 have been
observed through its effect on monocytes and macrophages [31],
while here we show that CCL2 may also influence the anti-tumour
immune response by affecting the ability of DCs to secrete IL-
12p70 but not other cytokines including IL-10, IL-1b, IL-6, IL-8
or TNF-a in response to LPS stimulation. In contrast, Braun et al.
have previously shown that CCL2 can inhibit IL-12p70
production from monocytes and this is pertussis toxin sensitive,
but they did not observe this reduction in IL-12p70 secretion from
dendritic cells treated with either SAC+IFNc or CD40L+IFNc
[33]. Alternatively, Omata et al. found DCs differentiated from
monocytes in the presence of CCL2 had a reduced capacity to
secrete IL-12p70 following stimulation with CD40 ligand, an effect
not sensitive to pertussis toxin. These authors reported no effect of
CCL2 on the differentiation or maturation of DCs. [34].
Therefore, the precise mechanism by which CCL2 exerts its effect
on DCs remains to be fully elucidated.
While the effect of CXCL1 and CXCL5 on DC maturation and
cytokine secretion has not been previously investigated, their
known function is to attract and activate neutrophils [14,15],
which in turn have been implicated with tumour cell growth,
angiogenesis and metastasis [35]. Since DCs express CXCR2 [19]
which is the receptor for CXCL1 and CXCL5, it is not surprising
that CXCL1 and CXCL5 could have an effect on DC function.
Chemokines such as CCL2, CXCL1 and CXCL5 signal through
G-protein coupled receptors, which control intracellular cAMP
levels and increased cAMP levels correlates with decreased IL-12
production [36]. However, the mechanism by which these
chemokines reduce IL-12p70 secretion from DCs is not known,
and it will be subject of our future investigations.
Interestingly CXCL1 and VEGF have an additive inhibitory
effect on IL-12p70 secretion. They act on different receptors
which have previously been shown to be present on DCs [7,19],
therefore they might activate different signalling pathways
simultaneously, or they could activate the same pathway more
effectively. VEGF has been shown to enhance phospho-ERK1 &
ERK2 in DCs and this pathway negatively regulates monocyte
derived DC maturation [7,37]. Which signalling pathways are
activated by CXCL1 through CXCR2 in dendritic cells is yet
unknown, however studies in different cell types, such as cancer
cells, show that CXCR2 signalling can activate NF-kB, STAT3
and the ERK pathways [38,39,40]. Hence, there are a variety of
potential mechanisms by which CXCR2 ligands may inhibit the
secretion of IL-12p70 by DCs. However, immune depleting either
of these cytokines singly or in combination with neutralising
antibodies did not reverse the inhibitory effect of the TCM. This
proves that it is probably multiple different factors acting together
that cause DC inhibition. This is consistent with previous research
showing that blocking of a single factor, VEGF in supernatants of
RCC-10 cells did not have a significant effect on DC activation
[22].
We observed that CCL2, CXCL1, CXCL5 and VEGF do not
block DC maturation, nor do they affect DC migration or T-cell
proliferation. Unlike DCs treated with TCM, the individual
inflammatory mediators do not enhance IL-10 however they all
Figure 5. CCL2, CXCL1, CXCL5 and VEGF inhibit IL-12p70
secretion by DCs in response to LPS. The supernatants of the DCs
cultured in the presence of CCL2, CXCL1, CXCL5 and VEGF (n=8) were
harvested and concentrations of IL-10 and IL-12p70 determined by
ELISA. Statistical significance was determined by the Mann-Whitney U
test. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0027944.g005
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CCL2, CXCL1, CXCL5 and VEGF. The explant tumour tissues
secrete many different soluble factors, and it is not very surprising
that a few isolated factors on their own do not have an effect
comparable to TCM. It is very likely that the many different
factors secreted into the TCM by the explant tumour act together
in inhibiting DC maturation and function. However the ability of
CCL2, CXCL1, CXCL5 and VEGF to significantly reduce IL-
12p70 production by DCs is important, as this may potentially
result in a reduced anti-tumour Th1 response in vivo.
In conclusion we found that TCM inhibits DC maturation, and
induces IL-10 while inhibiting IL-12p70 secretions from DCs. The
TCM components CCL2, CXCL1, CXCL5 and VEGF seem to
play a role in modulating the inflammatory response through
inhibition of IL-12p70 secretion by DCs, possibly to protect the
tumour from a potent immunologic response against it. In
addition, CXCL1 and VEGF act together in the inhibition of
IL-12p70 secretion from DCs. Even though CCL2, CXCL1,
CXCL5 and VEGF are present in the TCM at high levels, they
are not the main components of the TCM that affect DC
maturation and function. In conclusion, we have demonstrated the
importance of tumour conditioned media in regulating dendritic
cell function in colorectal cancer patients, however the underlying
mechanisms still need to be elucidated.
Materials and Methods
Ex vivo tumour explant culture
All tissue was obtained with the informed written consent of the
patient, and the protocol was approved by the Ethics Committee
of St. Vincent’s University Hospital.
Surgically resected colorectal cancer tumour tissue (n=21) and
normal tissue (.10cm from the tumour; n=5) was obtained from
patients from the Centre for Colorectal Disease’s explant tissue
bio-bank at St. Vincent’s University Hospital, Dublin (12 male, 9
female, median age 67, 1 Stage II, 5 Stage III, 15 Stage IV
Figure 6. The combination of CXCL1 and VEGF inhibits LPS induced IL-12p70 secretion by DCs. iDCs (n=5) were treated with a
combination of recombinant CXCL1 (100ng/mL) and VEGF (20 ng/mL), 4 hours prior to the addition of LPS (1 mg/mL). The cells were then cultured for
a further 18 hours and the levels of CD80, CD54, CD86, HLA-DR and CD83 were assessed by flow cytometry. Results are shown as fold-change in M.F.I.
relative to untreated iDCs. Statistical significance was determined by Wilcoxon signed rank test (A). Supernatants were removed from the cells treated
as described above and the concentration of IL-10 and IL-12p70 was determined by ELISA. Statistical significance was calculated by Mann-Whitney U
test (B). * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0027944.g006
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equal-sized pieces of approximately 5 mm
3 and cultured as
previously described [20]. Briefly, the explanted tumour tissues
were cultured for 72 h (in 24 well plates) in 2 mL RPMI 1640
containing 100 U/mL Penicillin, 100 mg/mL Streptomycin,
4 mg/mL Fungizone, 30 mg/mL gentamicin (Invitrogen; Carls-
bad, California) and supplemented with 20% foetal bovine serum
(Invitrogen). Following 72 hours in culture, Tumour Conditioned
Media (TCM) and normal conditioned media (NCM) was
collected and stored at 220uC until used for analyses.
Dendritic cell isolation and culture
Human monocyte-derived immature dendritic cells (iDCs) were
generated from peripheral blood mononuclear cells (PBMCs)
obtained from buffy coat preparations (National Blood Centre, St.
James Hospital, Dublin). Monocytes were isolated by positive
selection using CD14-magnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) and seeded at a density of 1610
6 cells/mL in
6-well plates in 3 mL of RPMI 1640 containing 100 U/mL
Penicillin, 100 mg/mL Streptomycin, 4 mg/mL Fungizone and
supplemented with 10% defined Hyclone foetal bovine serum
(Thermo Fisher Scientific, Waltham, MA, US), human granulo-
cyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/mL,
Immunotools, Friesoythe, Germany), and human IL-4 (70 ng/mL;
Immunotools). Cells were fed at day 3 by replacing half the
medium and adding fresh cytokines. At day 6 the cells exhibited an
immature DC phenotype (CD14
-, CD11c
+, CD86
-, CD54
low,
CD83
-, CD80
-, and HLA-DR
low).
Stimulation of monocyte derived DC
Freshly isolated iDC were plated in triplicate in 96 well plates at
1610
5 cells/200 ml in RPMI 1640 media supplemented with 10%
defined Hyclone FBS (Thermo Fisher Scientific), and stimulated
with 1 in 2, 1 in 4 and 1 in 10 dilution of Tumour Conditioned
Media (TCM) from 4 cultured explant tissues for 4 hours before
adding 1 mg/mL Escherichia coli lipopolysaccharide (LPS; Alexis
Biochemicals, Lausen, Switzerland) to determine the best dose of
TCM. Subsequently DCs were treated with a 1 in 2 dilution TCM
of all 21 patient explant tissues for 4 hours before adding 1 mg/mL
LPS. In addition, DCs were treated with a 1 in 2 dilution of NCM
of 5 patient explant tissues for 4 hours before 1 mg/ml LPS was
added. In separate experiments 1610
5 iDC/200 ml media were
treated with human recombinant 50 ng/mL CCL2 (MCP-1),
100 ng/mL CXCL1 (GROa), 100 ng/mL CXCL5 (ENA-78) and
20 ng/mL VEGF (R&D Systems, Abingdon, UK) for 4 hours
before 1 mg/mL LPS was added to the samples. Cultures were
incubated for a further 18 h at 5% CO2 and 37uC. In addition,
iDCs were cultured with a combination of cytokines (at the con-
centrations described above): CCL2+CXCL1, CCL2+CXCL5,
CCL2+VEGF, CXCL1+CXCL5, CXCL1+VEGF, CXCL5+
VEGF, CCL2+CXCL1+CXCL5+VEGF for 4 hours before LPS
was added for a further 18 hours. Supernatants were harvested
and levels of IL-10 and IL-12p70 secretion analysed and cells were
assessed for expression of maturation markers by flow cytometry as
described below.
Neutralising CXCL1 and VEGF in TCM
iDC were treated with TCM of 4 colorectal cancer patients, as
described above, with the addition of neutralising antibodies to
VEGF (Avastin,100 mg/mL), CXCL1 (15 mg/ mL, R&D systems)
and corresponding isotype control (15 mg/mL, R&D Systems) for
4 hours before LPS was added for 18 hours. Cells were assessed
for expression of maturation markers as described below, and
levels of IL-10 and IL-12p70 in the supernatant were analysed
using ELISA.
Flow cytometry
Dendritic cells were stained with the following monoclonal
antibodies (mAb): fluorescein isothiocyanate (FITC)-conjugated
anti-CXCR2 (R&D systems) anti-CD14 and anti-CD80; phycoer-
ythrin (PE)–conjugated anti-CD54; Phycoerythrin-Cy5 (PeCy5)–
conjugated anti-CD86 and anti-CD83; allophycocyanin (APC)–
conjugated anti-CD11c and anti-HLA-DR (all from BD Bioscienc-
es, Oxford, UK). Cells were also stained with corresponding isotype
control mAbs (BD Biosciences). Cells were acquired on FACSca-
libur flow cytometer and the data were analysed with CellQuest Pro
(BD Biosciences), or Flowjo software (Tree Star Inc., Ashland, OR).
Quantification of cytokines by ELISA
Levels of CCL2, CXCL1, CXCL5, and VEGF in TCM; IL-10
and IL-12p70 in DC supernatant; IFNc in T cell supernatant were
quantified by sandwich ELISA according to the manufacturer’s
protocol (R&D Systems). IL-1b, IL-6, IL-8 and TNF-a in DC
supernatants were measured by MSD multiplex assays as per
manufacturer’s instructions (Meso Scale Discovery, Sector Imager
2400, Gaithersburg, Maryland 20877).
Dendritic cell migration assay
Monocyte derived dendritic cells were seeded at 5610
5 cells/ml
in the upper chambers of 96 well plate (Corning B.V. Life
Sciences, Amsterdam, The Netherlands). CCL2, CXCL1,
CXCL5, VEGF and CCL19 (Immunotools) were added to the
lower chambers at 50 ng/ml and 150 ng/ml (n=3). Plates were
incubated for 4 hours at 37uC. Cells were counted using a Z1
Coulter Particle counter (Beckman Coulter Diagnostics Limited,
Lismeehan, O’Callahans Mills, Ireland).
T cell proliferation assay
CD3
+ T cells were isolated from PBMCs of healthy donors
using CD3-labelled magnetic beads (Miltenyi Biotec). The T cells
were labelled with CFSE (Molecular Probes, Eugene, OR). Briefly,
cells were incubated with 0.5 mM CFSE in PBS for 2.5 min. Heat
inactivated FBS (Invitrogen) was added to stop the reaction and
cells were washed prior to resuspension in complete RPMI. T cells
were incubated with DCs in round-bottomed 96-well plates for 5
days in a 10:1 ratio (T cells:DCs). Cells were harvested for flow
cytometric analysis and levels of IFNc in the supernatant were
determined by ELISA.
Intracellular IFNc
PBMC’s form healthy donors were incubated with DCs in a 10:1
ratio (PBMC: DCs) for 5 days. Cells were harvested and treated for
intracellular staining of IFNc as follows: Brefeldin A (10 mg/ml,
Sigma-Aldrich, Dublin, Ireland) phorbol myristate acetate (PMA)
(25 ng/ml, Sigma-Aldrich) and Ionomycin (1 mg/ml, Sigma-Aldrich)
wasadded tothe cellsfor 4 hourstostimulate cytokineproduction and
prevent secretion of these cytokines. The cells were stained with CD3-
APC (BD biosciences) before fixing the cells with 4% paraformalde-
hyde (Sigma-Aldrich) for 10 minutes and adding 0.2% w/v saponin
(Sigma-Aldrich) for another 10 minutes to permeabilise the cell
membrane. 5 ml of PE conjugated anti-IFNc (BD Biosciences) was
added and cells were analysed by flow cytometry.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
version 5.00 for Windows (GraphPad software, La Jolla, CA). The
Tumour Microenvironment Inhibits Dendritic Cells
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were used to compare groups as appropriate. For correlations the
Spearman rank test was used. A p-value of ,0.05 was considered
to be significant.
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